SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that
Kevin R. Lind, the Company's
Executive Vice President and Chief Financial Officer, will present
a corporate update at the 26th Annual Credit Suisse Healthcare
Conference on Wednesday, November 8
at 12:10pm MST. The conference
will take place November 6-8 at the
Phoenician in Scottsdale, AZ.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on
developing novel, small molecule drugs with optimized receptor
pharmacology designed to deliver broad clinical utility across
multiple therapeutic areas. Our proprietary pipeline includes
potentially first- or best-in-class programs for which we own
global commercial rights. Our three most advanced
investigational clinical programs are ralinepag (APD811) which has
completed a Phase 2 trial for pulmonary arterial hypertension
(PAH), etrasimod (APD334) in Phase 2 evaluation for multiple
autoimmune indications including ulcerative colitis (UC), and
APD371 in Phase 2 evaluation for the treatment of pain associated
with Crohn's disease. In addition, Arena has collaborations with
the following pharmaceutical companies: Eisai Co., Ltd. and Eisai
Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the upcoming
presentation; and Arena's focus, the potential of its programs, and
collaborations. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include those disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original
content:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-credit-suisse-healthcare-conference-on-november-8-300545970.html
SOURCE Arena Pharmaceuticals, Inc.